Newly approved Opdivo added $40 million to the quarter's product sales, which rose 8.9% compared to the year-earlier period.
Sales of the new cancer drug topped expectations since its February launch.
The manufacturer's SynchroMed drug-infusion pump was associated with 14 deaths.
PCSK9 antibodies reduced overall mortality and lowered LDL cholesterol levels in more than 10,000 patients in Phase-II/III clinical trials.
Merck said Januvia is not linked to higher heart-failure risk; Biogen plans to spend $2.5 billion on Alzheimer's disease; Mylan rejected Teva's bid
Briefing materials released before Wednesday's panel review indicate the regulator wants clearer data to assess Amgen's experimental melanoma treatment.
We know it's early days (the smartwatch been available for three days to be exact), but we'd like to know how it is going.
The Centers for Medicare and Medicaid Services last year published 4.45 million records about financial relationships between industry and HCPs.
More pharma companies hike drug prices post-acquisition; HCV linked to increased risk of cancer; a combined Teva-Mylan would control 25% of the US generic drug market
The 2015 healthcare agency questionnaire, for firms hoping to be featured in the Top 100 Agencies issue, is live. Click here to be considered.
- Sales rise as Amgen outlines cardiovascular strategy
- FDA says Amgen cancer data can't support accelerated approval
- Partners+Simons CEO takes helm at parent company Myelin Health
- Five things for pharma marketers to know: Thursday, April 23
- Five things for pharma marketers to know: Wednesday, April 22